Buscar
Mostrando ítems 11-20 de 196
Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
(PERGAMON-ELSEVIER SCIENCE LTD, 2009)
Chronic myeloid leukemia (CML) is a rare disease in childhood which is almost exclusively associated with bcr-abl p210 (M-bcr) rearrangements. It has been suggested that co-expression of p 190 and p210 may be a pathway of ...
Os desafios no tratamento da Leucemia mielóide crônica na era do mesilato de imatinibeChallenges in current chronic myeloid leukemia therapy of imatinib era
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2004)
Existence of periodic solutions in the modified Wheldon model of CML
(Texas State University. Department of Mathematics, 2013-10)
The Wheldon model (1975) of a chronic myelogenous leukemia (CML) dynamics is modified and enriched by introduction of a time-varying microenvironment and time-dependent drug efficacies. The resulting model is a special ...
Lack of cross-reactivity of lytic antibodies with bloodstream forms of Trypanosoma cruzi zymodemes generated in a mouse experimental model
(1995)
Immune sera from mice infected with specific Zymodemes of Trypanosoma cruzi parasites displayed preferential in vitro complement-mediated trypanolytic activity with homologous or genetically related bloodstream trypomastigotes. ...
Description of a new BCR-ABL point mutation in a CML patient with evolution to lymphoid blast crisis
(Pergamon-Elsevier B.V. Ltd, 2010-04-01)
MLL2/KMT2D and MLL3/KMT2C expression correlates with disease progression and response to imatinib mesylate in chronic myeloid leukemia
(BioMed Central, 2018)
Abstract
Background
Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm whose pathogenesis is linked to the Philadelphia chromosome presence that generates ...
ABCB1 haplotype is associated with major molecular response in chronic myeloid leukemia patients treated with standard-dose of imatinib
(ACADEMIC PRESS INC ELSEVIER SCIENCESAN DIEGO, 2012-02-15)
Background: Imatinib mesylate (IM) is a selective tyrosine kinase inhibitor used for treating chronic myeloid leukemia (CML). IM has high efficacy, however some individuals develop a resistance due to impaired bio-availability. ...
Carboxymethyl lignin as stabilizing agent in aqueous ceramic suspensions
(ELSEVIER SCIENCE BVAMSTERDAM, 2012)
Identifying new uses for residues of industries that process large quantities of biomass, as in bioethanol production, is essential for a sustainable development with reduced impact on the environment, which is the reason ...
The structure of waxy corn starch: Effect of granule size
(Wiley-v C H Verlag GmbhBerlinAlemanha, 1998)